耳鼻喉科Pubmed文献追踪每日 14:00 同步
← 返回全部文献
Article record

生物制剂与内镜鼻窦手术治疗原发性重度未控制CRSwNP：不同机制，互补作用

Biologics vs Endoscopic Sinus Surgery in Primary Severe Uncontrolled CRSwNP: Distinct Mechanisms, Complementary Roles.

综述 Meta鼻科IF 7.7Q1

文献信息

PMID42988468
原文在 PubMed 查看原文 ↗
发表日期2026
作者Martin Desrosiers
查看其他 5 位作者

Isam Alobid；Vibecke Backer；David Kennedy；Stella E Lee；Amber U Luong

作者单位Université de Montréal / Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. Electronic address: desrosiers_martin@hotmail.com.
查看其他 5 条单位信息

Hospital Clínic de Barcelona, CIBERES, IDIBAPS, Universitat Barcelona, Barcelona, Spain.；Department of Otorhinolaryngology-Head & Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.；Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pa.；Department of Otolaryngology-Head & Neck Surgery, Mass General Brigham, Harvard Medical School, Boston, Mass.；McGovern Medical School at the University of Texas Health Science Center at Houston, Tex.

期刊The journal of allergy and clinical immunology. In practice
SCI 分区Q1
IF7.7
研究类型综述 Meta · 临床
所属专科鼻科

中文摘要

内镜鼻窦手术（ESS）与生物制剂均为慢性鼻窦炎伴鼻息肉（CRSwNP）的有效治疗手段，但二者在机制上存在根本差异。将这些疗法理解为机制上截然不同而非可互换，对于优化患者选择和长期疾病控制至关重要。ESS作为一种局部、组织层面的干预，可清除炎症负荷并促进上皮恢复，而生物制剂则提供对2型炎症的全身性抑制。ESS与生物制剂治疗均安全且耐受性良好，是CRSwNP的良好治疗选择。尽管两种疗法在管理CRSwNP方面均有效，当前证据支持将ESS作为鼻内局部糖皮质激素治疗失败后的具有成本效益的一线干预，而生物制剂则保留用于难治性疾病或选定的高风险表型。

英文摘要

Endoscopic sinus surgery (ESS) and biologic therapies are both effective treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), yet they differ fundamentally in mechanism. Understanding these therapies as mechanistically distinct rather than interchangeable is essential for optimal patient selection and long-term disease control. ESS acts as a local, tissue-level intervention that removes inflammatory burden and enables epithelial recovery, whereas biologics provide systemic suppression of type 2 inflammation. Both ESS and biologic therapy are safe and well tolerated and represent good treatment options for CRSwNP. Despite effectiveness of both therapies in managing CRSwNP, current evidence supports ESS as a cost-effective first-line intervention following failure of intranasal topical corticosteroid therapy, with biologics reserved for refractory disease or selected high-risk phenotypes.